From the Drugbank Application to the Novel Drugs: A Pharmacogenomic Summary

Abstract

Computational drug research has grown in popularity in recent decades because to lower risks, time, cost, and resource needs as compared to traditional experimental approaches. The DrugBank application has expanded the number and quality of pharmacological activities and drug metabolic pathways depicted visually. The review elaborated a number of novel drugs and the molecular target mechanisms discovered with DrugBank. The study involves papers indexed by Scopus and Pub Med, the search uses a combination of the following keyword variants; “Drugbank AND Repurposing Drug”, “Drugbank AND Pharmacogenomic”. This study only used original articles in English that were published peer reviewed journals from October 2020 to November 2022. Thus, the screening results of library sources were narrowed to 9 original articles that met the inclusion criteria. Our result highlighted the involvement of 23 drug-targeting molecules in nine spesific diseases. The result shows 46 lists of repurposing drugs, four of which have the potential to be developed as prostate cancer treatments, five new drugs for ovarian cancer five new breast cancer drugs, eight new drugs highly recommended for depression, five candidates for atopic dermatitis, two recommended treatment for asthma, a novel drug for multiple sclerosis, and 18 potential medication for chronic hepatitis B.